These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

263 related items for PubMed ID: 22014129

  • 1. Tetrabenazine for the treatment of chorea and other hyperkinetic movement disorders.
    Jankovic J, Clarence-Smith K.
    Expert Rev Neurother; 2011 Nov; 11(11):1509-23. PubMed ID: 22014129
    [Abstract] [Full Text] [Related]

  • 2. Tetrabenazine for the treatment of hyperkinetic movement disorders: a review of the literature.
    Chen JJ, Ondo WG, Dashtipour K, Swope DM.
    Clin Ther; 2012 Jul; 34(7):1487-504. PubMed ID: 22749259
    [Abstract] [Full Text] [Related]

  • 3. Tetrabenazine in the treatment of hyperkinetic movement disorders.
    Kenney C, Jankovic J.
    Expert Rev Neurother; 2006 Jan; 6(1):7-17. PubMed ID: 16466307
    [Abstract] [Full Text] [Related]

  • 4. Tetrabenazine.
    Fasano A, Bentivoglio AR.
    Expert Opin Pharmacother; 2009 Dec; 10(17):2883-96. PubMed ID: 19929707
    [Abstract] [Full Text] [Related]

  • 5. An experimental model for Huntington's chorea?
    Zeef DH, Jahanshahi A, Vlamings R, Casaca-Carreira J, Santegoeds RG, Janssen ML, Oosterloo M, Temel Y.
    Behav Brain Res; 2014 Apr 01; 262():31-4. PubMed ID: 24412685
    [Abstract] [Full Text] [Related]

  • 6. Long-term tolerability of tetrabenazine in the treatment of hyperkinetic movement disorders.
    Kenney C, Hunter C, Jankovic J.
    Mov Disord; 2007 Jan 15; 22(2):193-7. PubMed ID: 17133512
    [Abstract] [Full Text] [Related]

  • 7. Tetrabenazine, a monoamine-depleting drug used in the treatment of hyperkinetic movement disorders.
    Guay DR.
    Am J Geriatr Pharmacother; 2010 Aug 15; 8(4):331-73. PubMed ID: 20869622
    [Abstract] [Full Text] [Related]

  • 8. [Therapeutic use of tetrabenazine].
    López Del Val LJ, López-García E, Martínez-Martínez L, Santos-Lasaosa S.
    Rev Neurol; 2010 Aug 15; 48(10):523-33. PubMed ID: 19434587
    [Abstract] [Full Text] [Related]

  • 9. VMAT2 inhibitors for the treatment of hyperkinetic movement disorders.
    Koch J, Shi WX, Dashtipour K.
    Pharmacol Ther; 2020 Aug 15; 212():107580. PubMed ID: 32454050
    [Abstract] [Full Text] [Related]

  • 10. Tetrabenazine treatment for Huntington's disease-associated chorea.
    Ondo WG, Tintner R, Thomas M, Jankovic J.
    Clin Neuropharmacol; 2002 Aug 15; 25(6):300-2. PubMed ID: 12469001
    [Abstract] [Full Text] [Related]

  • 11. A study of chorea after tetrabenazine withdrawal in patients with Huntington disease.
    Frank S, Ondo W, Fahn S, Hunter C, Oakes D, Plumb S, Marshall F, Shoulson I, Eberly S, Walker F, Factor S, Hunt V, Shinaman A, Jankovic J.
    Clin Neuropharmacol; 2008 Aug 15; 31(3):127-33. PubMed ID: 18520979
    [Abstract] [Full Text] [Related]

  • 12. Tetrabenazine therapy of pediatric hyperkinetic movement disorders.
    Jain S, Greene PE, Frucht SJ.
    Mov Disord; 2006 Nov 15; 21(11):1966-72. PubMed ID: 16958131
    [Abstract] [Full Text] [Related]

  • 13. Tetrabenazine treatment in movement disorders.
    Paleacu D, Giladi N, Moore O, Stern A, Honigman S, Badarny S.
    Clin Neuropharmacol; 2004 Nov 15; 27(5):230-3. PubMed ID: 15602104
    [Abstract] [Full Text] [Related]

  • 14. Short-term effects of tetrabenazine on chorea associated with Huntington's disease.
    Kenney C, Hunter C, Davidson A, Jankovic J.
    Mov Disord; 2007 Jan 15; 22(1):10-3. PubMed ID: 17078062
    [Abstract] [Full Text] [Related]

  • 15. Tetrabenazine therapy of dystonia, chorea, tics, and other dyskinesias.
    Jankovic J, Orman J.
    Neurology; 1988 Mar 15; 38(3):391-4. PubMed ID: 3279337
    [Abstract] [Full Text] [Related]

  • 16. The long-term effect of tetrabenazine in the management of Huntington disease.
    Fasano A, Cadeddu F, Guidubaldi A, Piano C, Soleti F, Zinzi P, Bentivoglio AR.
    Clin Neuropharmacol; 2008 Mar 15; 31(6):313-8. PubMed ID: 19050408
    [Abstract] [Full Text] [Related]

  • 17. Dopamine depleters in the treatment of hyperkinetic movement disorders.
    Jankovic J.
    Expert Opin Pharmacother; 2016 Dec 15; 17(18):2461-2470. PubMed ID: 27819145
    [Abstract] [Full Text] [Related]

  • 18. Tetrabenazine as anti-chorea therapy in Huntington disease: an open-label continuation study. Huntington Study Group/TETRA-HD Investigators.
    Frank S.
    BMC Neurol; 2009 Dec 18; 9():62. PubMed ID: 20021666
    [Abstract] [Full Text] [Related]

  • 19. Deutetrabenazine: Treatment of hyperkinetic aspects of Huntington's disease, tardive dyskinesia and Tourette syndrome.
    Paton DM.
    Drugs Today (Barc); 2017 Feb 18; 53(2):89-102. PubMed ID: 28387387
    [Abstract] [Full Text] [Related]

  • 20. Long-term effects of tetrabenazine in hyperkinetic movement disorders.
    Jankovic J, Beach J.
    Neurology; 1997 Feb 18; 48(2):358-62. PubMed ID: 9040721
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.